These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 35466857)

  • 1. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 5. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
    Azizi A; Houshyar R; Mar N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab vedotin - next game-changer in urothelial cancer.
    Maas M; Stühler V; Walz S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
    Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
    Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
    Taoka R; Kamada M; Izumi K; Tanimoto R; Daizumoto K; Hayashida Y; Uematsu K; Arai H; Sano T; Saito R; Hirama H; Kobayashi T; Honda T; Osaki Y; Abe Y; Naito H; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Ueda N; Sugimoto M
    Int J Clin Oncol; 2024 May; 29(5):602-611. PubMed ID: 38418804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
    N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
    Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
    Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 Jul; 19(4):635-644. PubMed ID: 38807017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
    Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
    Pace A; Brower B; Conway D; Leis D
    Clin J Oncol Nurs; 2021 Apr; 25(2):E1-E9. PubMed ID: 33739346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.